Payment overview · 2025
General Payments
$791.27
29 reported records · 12 companies
Healthcare provider profile · identity verified
Michael A Silao, M.D.
Allopathic & Osteopathic Physicians|General Practice · LOS ANGELES, CA · NPI 1497706147
Verified facts
What the public records show
CMS Open Payments records show Michael A Silao, M.D. received $791.27 in general payments during 2025 across 29 reported records.
Amgen Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Edarbyclor by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $165.08 | 20.9% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $134.99 | 17.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.30 | 14.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.01 | 11.0% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $64.77 | 8.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.46 | 7.1% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.91 | 5.2% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $30.87 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.14 | 3.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.93 | 3.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.20 | 2.9% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.61 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $791.27 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $105.62 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $98.32 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.23 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.23 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $83.46 | 3 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $64.77 | 1 | 2025 |
Source payment records
|
|||||
| PICO Normalized: pico |
Device | Smith+Nephew, Inc. | $64.77 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $59.46 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $30.87 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 247 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
247 | 55 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
247 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 358 | 112 |
| Famotidine | Famotidine | 251 | 66 |
| Jardiance | Empagliflozin | 247 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 238 | 74 |
| Eliquis | Apixaban | 235 | 33 |
| Gabapentin | Gabapentin | 229 | 52 |
| Losartan Potassium | Losartan Potassium | 222 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 63 |
| Lisinopril | Lisinopril | 200 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 60 |
| Metformin Hcl | Metformin Hcl | 178 | 59 |
| Furosemide | Furosemide | 154 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 22 |
| Metformin Hcl Er | Metformin Hcl | 124 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 27 |
| Omeprazole | Omeprazole | 110 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 21 |
| Allopurinol | Allopurinol | 102 | 31 |
| Carvedilol | Carvedilol | 98 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 33 |
| Atenolol | Atenolol | 91 | 26 |
| Ibuprofen | Ibuprofen | 91 | 25 |
| Celecoxib | Celecoxib | 88 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 13 |
| Trazodone Hcl | Trazodone Hcl | 85 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 17 |
| Finasteride | Finasteride | 78 | 23 |
| Alendronate Sodium | Alendronate Sodium | 73 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 33 |
| Baclofen | Baclofen | 71 | 18 |
| Donepezil Hcl | Donepezil Hcl | 71 | 18 |
| Entresto | Sacubitril/Valsartan | 69 | 12 |
| Ozempic | Semaglutide | 69 | 16 |
| Lorazepam | Lorazepam | 68 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 21 |
| Montelukast Sodium | Montelukast Sodium | 67 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 21 |
| Farxiga | Dapagliflozin Propanediol | 65 | 11 |
| Tramadol Hcl | Tramadol Hcl | 65 | 19 |
| Memantine Hcl | Memantine Hcl | 60 | 14 |
| Simvastatin | Simvastatin | 58 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 58 | 27 |
| Mirtazapine | Mirtazapine | 57 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Cephalexin | Cephalexin | 51 | 39 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 48 | 16 |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 18 |
| Meloxicam | Meloxicam | 44 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Glipizide | Glipizide | 41 | 15 |
| Alprazolam | Alprazolam | 39 | 11 |
| Spironolactone | Spironolactone | 39 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 11 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Azithromycin | Azithromycin | 31 | 24 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | 15 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 11 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | 13 |
| Valsartan | Valsartan | 27 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Alogliptin | Alogliptin Benzoate | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Digoxin | Digoxin | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Colchicine | Colchicine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $791.27 · 29 records | Amgen Inc. | APRETUDE, COLLAGENASE SANTYL, CRYSVITA, HORIZANT, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, OTEZLA, PICO, REPATHA, The Cologuard Plus Collection Kit, VOQUEZNA, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Azurity Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error